Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic Abnormalities

Project: Types of projects

  • Gerstoft, Jan, The Capital Region of Denmark Rigshospitalet, Denmark (Project participant)
  • Hansen, Ann-Britt E, Odense University Hospital, Denmark (Project participant)
  • Pedersen, Court, Odense University Hospital, Denmark (Project participant)
  • Mathiesen, Lars Reinhardt (Project participant)
  • Laursen, Alex, Aarhus University Hospital, Denmark (Project participant)
View graph of relations
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including peripheral lipoatrophy. The main hypothesis of the study is that switching from thymidine-analogue based HAART will reverse lipoatrophy. We plan to perform an observational study recruiting up to 100 HIV-infected patients receiving Trizivir (zidovudine/lamivudine/abacavir). The patients will be offered an NRTI or lopinavir/ritonavir instead of zidovudine or they can choose to continue with Trizivir. The main endpoint is changes in peripheral fat mass as determined by DEXA-scanning.
StatusCurrent
Period01/03/200431/05/2007
URLhttp://clinicaltrials.gov/ct/show/NCT00139178?order=18
Research programme<ingen navn>

ID: 32505851